Genomics BioSci & Tech. Co.,Ltd.

    Genomics BioSci & Tech. Co.,Ltd.

    TTPEX:4195
    17.00
    TWD
    +0.45
    (+2.72%)

    Share Statistics

    As of December 31, 2025, Genomics BioSci & Tech. Co.,Ltd. has 72.45M shares outstanding.

    Shares Outstanding72.45M

    Enterprise Valuation

    These figures are as of December 31, 2025. The EV/Sales ratio of 0.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Genomics BioSci & Tech. Co.,Ltd. trades at an EV/FCF ratio of 38.78, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

    EV / Sales0.71
    EV / FCF38.78

    Financial Position

    As of December 31, 2025, Genomics BioSci & Tech. Co.,Ltd. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 107.93, indicating elevated leverage, while an interest coverage ratio of -5.03 demonstrates limited ability to service its debt obligations.

    Current Ratio1.20
    Quick Ratio0.37
    Debt / Equity107.93
    Debt / EBITDA-8.42
    Interest Coverage-5.03

    Financial Efficiency

    Over the twelve months ended December 31, 2025, Genomics BioSci & Tech. Co.,Ltd. posted a negative return on equity (ROE) of -7.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.83, reflecting losses generated across the asset base. Inventory turnover of 2.26 indicates how many times Genomics BioSci & Tech. Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

    Return on Equity (ROE)-7.80
    Return on Assets (ROA)-2.83
    Inventory Turnover2.26

    Stock Price Statistics

    TWD

    As of the close on June 4, 2026, Genomics BioSci & Tech. Co.,Ltd.'s stock has declined approximately 7.61% over the past 52 weeks. The 50-day moving average sits at 24.85, while the 200-day moving average is 24.85.

    52-Week Price Change-7.61%
    50-Day Moving Average24.85
    200-Day Moving Average24.85

    Margins

    Over the twelve months ended December 31, 2025, Genomics BioSci & Tech. Co.,Ltd. posted a gross margin of 32.66, reflecting its pricing power and cost economics. The operating margin of -10.53 and net profit margin of -5.57 provide insight into operational efficiency.

    Gross Margin32.66
    Operating Margin-10.53
    Pretax Margin-9.55
    Profit Margin-5.57
    EBITDA Margin-10.53

    Stock Splits

    Genomics BioSci & Tech. Co.,Ltd.'s most recent stock split took place on August 8, 2023 with a 50:51 split ratio.

    Last Split Date8/8/2023
    Split Ratio50:51

    Scores

    As of December 31, 2025, Genomics BioSci & Tech. Co.,Ltd. has an Altman Z-Score of 0.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

    Altman Z-Score0.20